Cyient DLM Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/jvc7r1h6ad6zgtsihm6v6fra.pdf

Key Takeaways


Revenue & Volume: The Q1 Miss and Q2 Catch-Up

Krishna Bodanapu: "the pipeline is already in excess of a billion dollars and even weighted, it's almost half a billion dollars. So, we are quite confident of building up that pipeline. I don't see that to be a challenge to deliver a 30% CAGR over the next three years."

Margins: Absorption, Mix and the Build-to-Spec Path

Anthony Montalbano: "the Build-to-Spec programs will deliver higher margins. I think the mid-teens, if our base business is less than say delivering 10 and Build-to-Spec program maybe could be delivering 13%-14% or maybe even a little bit more depending on that specific program."

Order Book & Pipeline: Lumpy but Record-Sized

Anthony Montalbano: "the nature of our business with a relatively few number of clients. And we kind of use the term that it can be lumpy in terms of how it's delivered and this is still similar from an order book perspective as well."

Strategic Expansion: India Defense, ITAR, M&A and New Sectors

Shrinivas Kulkarni: "our intent is to sort of acquire companies which will not be diluted at least at an EBITDA level for us, because of amortization and other things, it could be dilutive at EBIT level."

Balance Sheet & Cash Flow


Guidance & Commitments

CommitmentSpecificsTimeline
Q1 shortfall recoveryShortfall filled into Q2; H1 budget will be metEnd of next month / H1 close
Revenue CAGR30% CAGR over three-year periodThree-year horizon
Near-term EBITDA marginDouble-digit (10%–11%)Near term
Net working capital daysRoughly 100 daysBy end of Q3
Free cash flowAt least break even, if not profitFull year
Industrial key-client recoveryDemand from inventory-burning client returnsH2
Build-to-Spec margin contributionNegligible this fiscal year (<5% of revenue); mid-teens margins as share grows2–4 years
M&A announcementOne opportunity in very advanced stages; IPO proceeds used this yearThis fiscal year

Key Metrics

MetricQ1 FY25
Revenue₹257.9 cr, +18.8% YoY
EBITDA₹20 cr, flat YoY
EBITDA margin7.8%, lower absorption due to volume shortfall
PAT growth+97.7% YoY
PAT marginup 164 bps YoY
Gross marginflat YoY; improvement expected as volume picks up
Order bookdeclined sequentially for 8 quarters; lumpy, H2-weighted
Revenue mix: Aerospace & Defense63% of revenue (26% Aerospace, 37% Defense)
Revenue mix: H1 vs H2H1 ~40%, H2 ~60% historically
Capacity utilization~55%
Build-to-Spec revenue shareless than 5% of revenue expected in FY25
Build-to-Spec margin potential13%-14% or higher, vs base business below 10%
Net working capital days171 days in Q1; target of ~100 days by end of Q3 maintained
Customer advancesflat at 28%
IPO proceeds utilized~38% in one year since July 10, 2023
Pipelinein excess of $1 bn, weighted pipeline almost $0.5 bn
New logo wins4 in Q1: semiconductor, defense, med tech, aerospace & defense